Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

@inproceedings{NoyanAshraf2009AgonistLA,
  title={Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice},
  author={Mohammad Hossein Noyan-Ashraf and Mohammed Abdul Momen and Kiwon Ban and Aparecida Sadi and Yu-qing Zhou and Abdolmehdi Riazi and Laurie L. Baggio and R. Mark Henkelman and M. Kazim Husain and Daniel J Drucker},
  year={2009}
}
RESULTS—Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P 0.0001) and infarct size (21 2% versus 29 3%, P 0.02) and improved cardiac output (12.4 0.6 versus 9.7 0.6 ml/min; P 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3 , PPAR… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart

  • DP Sonne, T Engstrom, M Treiman
  • Regul Pept 146:243–249,
  • 2008
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…